Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
about
Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyGlatiramer acetate for multiple sclerosisDaclizumab treatment for multiple sclerosis.Chemotherapeutics in the treatment of multiple sclerosis.Aggressive multiple sclerosis: proposed definition and treatment algorithm.Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumabEfficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis.From injection therapies to natalizumab: views on the treatment of multiple sclerosis.Cancer cell spheroids as a model to evaluate chemotherapy protocols.Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.Induction therapy for patients with multiple sclerosis: why? When? How?Long-term evolution of multiple sclerosis disability in the treatment era.Update on the treatment options for multiple sclerosis.Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update.Back to the future for multiple sclerosis therapy: focus on current and emerging disease-modifying therapeutic strategies.A critical appraisal of treatment decisions in multiple sclerosis--old versus new.Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence.Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.The current role of mitoxantrone in the treatment of multiple sclerosis.Multiple sclerosis and the role of immune cells.Balancing Early Aggression Against Risk of Progression in Multiple Sclerosis.Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study.Beta-interferons in multiple sclerosisSerial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.The heritage of glatiramer acetate and its use in multiple sclerosisRole of Natural Killer Cells in Multiple Sclerosis
P2860
Q22241650-0E95CECC-52E2-4C49-9C33-8DBE23373C4DQ24235498-613C6702-B878-463F-A387-5838928587D3Q33382919-B5A3C350-75DD-4347-B5CE-9655ED4B12D1Q34409536-9C27151C-D92C-482C-87F4-AE436915C7EEQ34478828-E4B02826-A5DE-4ECC-8932-54B8E5A606EFQ35205472-671C145E-EEC2-4F2B-9FBE-505301EF770BQ35276622-AC9F7B85-BC6A-4962-BD7C-BDA4195A2ECDQ35654037-797CF90D-6C18-4C7F-A427-E574726CF7D8Q35825914-6A19F7F2-D772-41C2-B906-BE11D801FDD5Q36312156-9022EA63-4269-4DEE-8277-418169D2CCFEQ36730633-4762E13D-B44A-43A1-AAF0-EC290CFEFF36Q36923587-E307FD9A-E3DB-4326-8EDC-7767402192B3Q37409279-9D443AE0-E6B9-47F0-9E0B-C9A8CF26B74EQ37729045-7D4A05B7-6F5A-419D-AADA-4BDE6D754E60Q37732340-2D9CC18F-FB67-445F-873F-973DD523F90DQ37773270-D9160811-9767-4D79-B6F9-645CAA47C2A8Q37862062-4AFDA52B-7E54-46CF-85C1-DF89FBFB4119Q37976344-51437F73-5829-4370-B70B-9983EC5E6110Q37997089-BED4A02E-433C-41C2-B36A-1BBF63667496Q38152977-2D913DC7-C561-4766-9391-662C269C3C47Q38212259-4A85BA6F-A2B4-404A-8737-F22BA637BC19Q38254152-9174551B-75E7-4414-A0FC-74C8B427B8F0Q38649412-6B982053-8B8E-4BB0-9D9B-61E11B6BA6C3Q39021942-0CB0BE3E-9E0D-489E-9AF7-1AE5C2CEA5CBQ41447681-E53A30F5-8E2B-4275-8598-0CA033097111Q42573463-AB2D5A20-241F-4138-AB4E-E73C6F3D6E83Q43295185-F5737988-5E07-4319-9795-815EC399DFACQ45066717-C6E2A868-E6D8-4545-B332-ABB2D6FEB960Q56804781-2779448F-2BEF-426F-A6F4-3B3743212B2CQ58692418-E92163C9-0AEA-4458-9573-C1F081A55D1E
P2860
Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Glatiramer acetate after induc ...... relapsing multiple sclerosis.
@ast
Glatiramer acetate after induc ...... relapsing multiple sclerosis.
@en
Glatiramer acetate after induc ...... relapsing multiple sclerosis.
@nl
type
label
Glatiramer acetate after induc ...... relapsing multiple sclerosis.
@ast
Glatiramer acetate after induc ...... relapsing multiple sclerosis.
@en
Glatiramer acetate after induc ...... relapsing multiple sclerosis.
@nl
prefLabel
Glatiramer acetate after induc ...... relapsing multiple sclerosis.
@ast
Glatiramer acetate after induc ...... relapsing multiple sclerosis.
@en
Glatiramer acetate after induc ...... relapsing multiple sclerosis.
@nl
P2093
P2860
P356
P1476
Glatiramer acetate after induc ...... relapsing multiple sclerosis.
@en
P2093
D Campagnolo
D L Arnold
M S Freedman
P2860
P304
P356
10.1177/1352458507085759
P577
2008-04-18T00:00:00Z